Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

Home >> Signaling Pathways >> MAPK Signaling

MAPK Signaling

Products for  MAPK Signaling

  1. Cat.No. Product Name Information
  2. GN10814 Quercitrin Quercitrin Chemical Structure
  3. GN10804 Isovitexin Isovitexin Chemical Structure
  4. GN10784 Rhoifolin Rhoifolin Chemical Structure
  5. GN10752 Pachymic acid Pachymic acid Chemical Structure
  6. GN10709 Polyphyllin A Polyphyllin A Chemical Structure
  7. GN10664 Honokiol Honokiol Chemical Structure
  8. GN10590 Bakuchiol Bakuchiol Chemical Structure
  9. GN10494 Astragaloside IV Astragaloside IV Chemical Structure
  10. GN10481 Corynoxeine Corynoxeine Chemical Structure
  11. GN10409 cor-nuside cor-nuside Chemical Structure
  12. GN10336 Daphnetin Daphnetin Chemical Structure
  13. GN10307 Ginsenoside Re Ginsenoside Re Chemical Structure
  14. GN10267 Loureirin B Loureirin B Chemical Structure
  15. GN10248 Hesperitin Hesperitin Chemical Structure
  16. GN10063 Arctigenin Arctigenin Chemical Structure
  17. GN10023 Isorhamnetin Isorhamnetin Chemical Structure
  18. GN10016 Carnosol Carnosol Chemical Structure
  19. GC17577 NQDI 1 A selective inhibitor of ASK1 NQDI 1 Chemical Structure
  20. GC10282 Piperlongumine An alkaloid with anticancer and antioxidant activities Piperlongumine Chemical Structure
  21. GC17255 Gliotoxin An immunosuppressive mycotoxin with diverse biological effects Gliotoxin Chemical Structure
  22. GC11076 XMD8-92 A selective ERK5 inhibitor XMD8-92 Chemical Structure
  23. GC12691 XMD17-109 A selective ERK5 inhibitor XMD17-109 Chemical Structure
  24. GC13115 VX-11e A selective ERK inhibitor VX-11e Chemical Structure
  25. GC15260 Trametinib DMSO solvate Trametinib DMSO solvate Chemical Structure
  26. GC13578 Skepinone-L An inhibitor of p38 MAPK Skepinone-L Chemical Structure
  27. GC16001 SCH772984

    A selective inhibitor of ERK1/2

     SCH772984 Chemical Structure
  28. GC10054 SB 239063 A selective p38 MAPK inhibitor SB 239063 Chemical Structure
  29. GC14534 Regorafenib monohydrate A multi-kinase inhibitor Regorafenib monohydrate Chemical Structure
  30. GC14606 Regorafenib hydrochloride A multi-kinase inhibitor Regorafenib hydrochloride Chemical Structure
  31. GC13514 NG25 An inhibitor of MAP4K2 and TAK1 NG25 Chemical Structure
  32. GC11649 MLN 2480 An oral pan-Raf kinase inhibitor MLN 2480 Chemical Structure
  33. GC11277 MEK inhibitor MEK inhibitor Chemical Structure
  34. GC13841 JNK-IN-8 A selective, irreversible JNK inhibitor JNK-IN-8 Chemical Structure
  35. GC15028 JNK-IN-7 A non-selective JNK inhibitor JNK-IN-7 Chemical Structure
  36. GC14125 FMK An inhibitor of RSK2 FMK Chemical Structure
  37. GC14114 DB07268 A potent inhibitor of JNK1 DB07268 Chemical Structure
  38. GC12486 Dabrafenib Mesylate (GSK-2118436) A Raf kinase inhibitor Dabrafenib Mesylate (GSK-2118436) Chemical Structure
  39. GC14337 Cobimetinib (R-enantiomer) Cobimetinib (R-enantiomer) Chemical Structure
  40. GC17426 Cobimetinib (racemate) Cobimetinib (racemate) Chemical Structure
  41. GC10033 Cobimetinib A potent, orally available MEK1 inhibitor Cobimetinib Chemical Structure
  42. GC14693 CMK CMK Chemical Structure
  43. GC17860 CEP-32496 hydrochloride A potent inhibitor of B-Raf CEP-32496 hydrochloride Chemical Structure
  44. GC10446 CC-930 A potent JNK inhibitor CC-930 Chemical Structure
  45. GC14197 CC-401 hydrochloride A potent, specific pan-JNK inhibitor CC-401 hydrochloride Chemical Structure
  46. GC12151 B-Raf inhibitor B-Raf inhibitor Chemical Structure
  47. GC12482 BRAF inhibitor BRAF inhibitor Chemical Structure
  48. GC10918 AT7867 dihydrochloride A potent and orally bioavailable pan-Akt inhibitor AT7867 dihydrochloride Chemical Structure
  49. GC12882 AS 602801 A selective, orally bioavailable JNK inhibitor AS 602801 Chemical Structure
  50. GC13508 Trametinib (GSK1120212)

    An inhibitor of MEK1 and MEK2

     Trametinib (GSK1120212) Chemical Structure
  51. GC14732 PLX-4720 An orally-available inhibitor of the B-raf mutant B-RafV600E PLX-4720 Chemical Structure
  52. GC10397 PD0325901

    A MEK inhibitor that sustains stem cell renewal

     PD0325901 Chemical Structure
  53. GC17369 Sorafenib

    A multi-kinase inhibitor

     Sorafenib Chemical Structure
  54. GC13412 Vemurafenib (PLX4032, RG7204)

    An inhibitor of mutant V600E and wild type B-Raf

     Vemurafenib (PLX4032, RG7204) Chemical Structure
  55. GC15299 Staurosporine(CGP 41251) A potent inhibitor of protein kinase C Staurosporine(CGP 41251) Chemical Structure
  56. GP10075 PKA inhibitor fragment (6-22) amide

    A synthetic peptide inhibitor of PKA

     PKA inhibitor fragment (6-22) amide Chemical Structure
  57. GC25982 Tanzisertib(CC-930) Tanzisertib (CC-930, JNK-930, JNKI-1) is kinetically competitive with ATP in the JNK-dependent phosphorylation of the protein substrate c-Jun and potent against all isoforms of JNK (Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM) and selective against MAP kinases ERK1 and p38a with IC50 of 0.48 and 3.4 μM respectively. Tanzisertib(CC-930) Chemical Structure
  58. GC25521 IMM-H007 IMM-H007, an adenosine derivative, is an activator of AMP-Activated Protein Kinase (AMPK). IMM-H007 is a potential drug for treating cardiac dysfunction. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 (ATP binding cassette subfamily a member 1) degradation and facilitates its cell-surface localization in macrophages, thereby promotes cholesterol efflux. IMM-H007 Chemical Structure
  59. GC25420 Fipexide hydrochloride Fipexide (hydrochloride) is a psychoactive drug of the piperazine class. Fipexide hydrochloride Chemical Structure
  60. GC25289 CompK CompK (compound K), a potent and selective hematopoietic progenitor kinase 1 (HPK1 or MAP4K1) small molecule inhibitor, significantly improves human T-cell functions, with enhanced T-cell receptor avidity to recognize tumor-associated antigens and tumor cytolytic activity by CD8+ T cells. CompK Chemical Structure
  61. GC68350 Tinlorafenib Tinlorafenib Chemical Structure
  62. GC67964 Exarafenib Exarafenib Chemical Structure
  63. GC67905 ERK1/2 inhibitor 7 ERK1/2 inhibitor 7 Chemical Structure
  64. GC67800 B-Raf IN 11 B-Raf IN 11 Chemical Structure
  65. GC65978 B-Raf IN 10 B-Raf IN 10 (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. B-Raf IN 10 shows antitumor activity. B-Raf IN 10 Chemical Structure
  66. GC65949 GNE-9815 GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for CRAF and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers. GNE-9815 Chemical Structure
  67. GC65917 Andrograpanin Andrograpanin, a bioactive compound from Andrographis paniculata, exhibits anti-inflammatory and anti-infectious properties. Andrograpanin Chemical Structure
  68. GC65510 ERK1/2 inhibitor 1 ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively. ERK1/2 inhibitor 1 Chemical Structure
  69. GC65479 PROTAC B-Raf degrader 1 PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf based on Cereblon ligand with anti-cancer activity. PROTAC B-Raf degrader 1 Chemical Structure
  70. GC65329 EW-7195 EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung. EW-7195 Chemical Structure
  71. GC65303 Jaspamycin Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC50 of 6.5 nM and Kd of 8 nM in Trypanosoma brucei. Jaspamycin Chemical Structure
  72. GC65298 DMX-5804 DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). DMX-5804 Chemical Structure
  73. GC65297 MW-150 MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 Chemical Structure
  74. GC64904 MAP855 MAP855 is a highly potent, selective, ATP-competitive and orally active MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2. MAP855 Chemical Structure
  75. GC64828 PLX7922 PLX7922, a RAF inhibitor, can bind with BRAFV600E. PLX7922 inhibits pERK in BRAFV600E cell lines, and activates pERK in mutant NRAS cell lines. PLX7922 Chemical Structure
  76. GC64634 MLK-IN-1 MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1. MLK-IN-1 Chemical Structure
  77. GC64580 MMI-0100 MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 Chemical Structure
  78. GC64550 B-Raf IN 2 B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer. B-Raf IN 2 Chemical Structure
  79. GC64496 EF24 EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK. EF24 Chemical Structure
  80. GC64460 8-Chloro-cAMP 8-Chloro-cAMP is a cAMP analogue that induces growth arrest, and modulates cAMP-dependent PKA activity. 8-Chloro-cAMP has anticancer activity. 8-Chloro-cAMP Chemical Structure
  81. GC64292 MS432 MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for MEK1 and MEK2. MS432 displays good plasma exposure in mice, exhibiting DC50 values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively. MS432 Chemical Structure
  82. GC64287 SR15006 SR15006 is a inhibitor of Krüppel-like factor 5 (KLF5) with an IC50 of 41.6 nM in DLD-1/pGL4.18hKLF5p cells). SR15006 Chemical Structure
  83. GC64035 Hirsutenone Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone Chemical Structure
  84. GC63903 (E)-Osmundacetone (E)-Osmundacetone is the isomer of Osmundacetone. (E)-Osmundacetone Chemical Structure
  85. GC49700 Takeda-6d Takeda-6d Chemical Structure
  86. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide Chemical Structure
  87. GP23504 FLRT3 Human Fibronectin Leucine Rich Transmembrane Protein 3 Human Recombinant FLRT3 Human Chemical Structure
  88. GP23419 ESAT6 Early Secretory Target Mycobacterium Tuberculosis Recombinant ESAT6 Chemical Structure
  89. GC63700 5,6,7-Trimethoxyflavone 5,6,7-Trimethoxyflavone is a novel p38-α MAPK inhibitor with an anti-inflammatory effect. 5,6,7-Trimethoxyflavone Chemical Structure
  90. GC63680 MLKL-IN-2 MLKL-IN-2 is a MLKL inhibitor extracted from patent WO2021224505A1, compound (i). MLKL-IN-2 Chemical Structure
  91. GC63569 HPK1-IN-4 HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC50 of 0.061 nM) as preclinical immunotherapy tool compound. HPK1-IN-4 Chemical Structure
  92. GC63554 PD0325901-O-C2-dioxolane PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader. PD0325901-O-C2-dioxolane Chemical Structure
  93. GC63459 ERK-IN-3 benzenesulfonate ERK-IN-3 benzenesulfonate is a potent and orally active inhibitor of ERK. ERK-IN-3 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC50 values. ERK-IN-3 benzenesulfonate can be used for the research of cancers driven by RAS mutations. ERK-IN-3 benzenesulfonate Chemical Structure
  94. GC63441 CC-99677 CC-99677 is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). CC-99677 Chemical Structure
  95. GC63425 Zunsemetinib Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib Chemical Structure
  96. GC63317 HPK1-IN-8 HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length HPK1. HPK1-IN-8 Chemical Structure
  97. GC63264 Zapnometinib Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM. Zapnometinib Chemical Structure
  98. GC63176 Rp-cAMPS sodium salt Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (Kis of 12.5 ?M and 4.5 ?M, respectively) antagonist. Rp-cAMPS sodium salt Chemical Structure
  99. GC63144 PF-05381941 PF-05381941 is a potent dual inhibitor of TAK1/p38α, with IC50s of 156 and186 nM, respectively. PF-05381941 Chemical Structure
  100. GC63059 MAP4K4-IN-3 MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. MAP4K4-IN-3 Chemical Structure
  101. GC63006 HPK1-IN-7 HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1. HPK1-IN-7 Chemical Structure

Items 1 to 100 of 497 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction